Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Dean Schorno, James Bartley, Evan Jones, Matthew Rabinowitz, and More


Adaptive Biotechnologies has appointed Dean Schorno as its CFO. Schorno joins Adaptive after 13 years at Genomic Health where he held various leadership positions, including serving most recently as CFO.

With Schorno on its executive leadership team, Adaptive hopes to more smoothly transition from a life sciences research company to a firm commercializing clinical diagnostics, such as clonoSEQ, a test for measuring minimal residual disease in blood cancers. At Adaptive, Schorno will be in charge of the firm's financial infrastructure, as well as lead the management of its investor relations, human resources, and facilities.

The American College of Medical Genetics & Genomics has announced the election of four new directors to the board of its Foundation for Genetic and Genomic Medicine. The four directors are James Bartley, director of the California Children's Services Metabolic Specialty Care Clinic at Miller Children's Hospital in Long Beach; Evan Jones, co-founder and CEO of Digene Corporation; Matthew Rabinowitz, founder and president of Natera; and David Whiteman, senior medical director and global clinical sciences leader at Shire Human Genetics Therapies.

Michael Hayden, president of global R&D and CSO of Teva Pharmaceuticals, has received the Personalized Medicine World Conference's 2014 Luminary Award. He is being recognized for his work in advancing genetics research.

Hayden is credited with developing the first genetic test for Huntington disease and for the discovery of several genes associated with rare illnesses. His work to elucidate biological disease pathways has increased researchers' understanding of illnesses and led to new treatments, such as Glybera, the first gene therapy with regulatory approval.

Previous recipients of PMWC's Luminary Award, include Lee Hood, co-inventor of the first DNA sequencers; George Church, co-developer of the Human Genome Project; Brian Druker, co-inventor of the leukemia drug Gleevec; Janet Woodcock, director of the Center for Drug Evaluation & Research at the US Food and Drug Administration; Kim Popovits, CEO of Genomic Health; and Jay Flatley, CEO of Illumina.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.